Search

everythinglearnresearchcommunity

for

Search:↓

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

Finasteride does not prevent bladder cancer.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.

Androgens may influence bladder cancer progression by affecting cellular behavior.

5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.

Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.

Polypoid cystitis can mimic bladder cancer but can be effectively treated with surgery, stents, and medication.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

Finasteride use is linked to a lower risk of bladder cancer, especially in Caucasians and Hispanics.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Urologic diseases and treatments in older men can negatively affect fertility, and doctors should talk to patients about this.

Dutasteride may help shrink prostate cancer tumors.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Male cancer patients have a higher risk of severe illness and death from COVID-19 than female patients.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Tissue-derived extracellular vesicles are crucial for cancer diagnosis, prognosis, and treatment.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.

KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.